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Abstract
Background: Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells primarily in the
bone marrow. Bisphosphonates (BP) are used as supportive therapy in the management of MM. This study aimed
to analyze the incidence, risk factors, and clinical outcomes of medication-related necrosis of the jaw (MRONJ) in
MM patients.
Methods: One hundred thirty MM patients who had previous dental evaluations were retrospectively reviewed.
Based on several findings, we applied the staging and treatment strategies on MRONJ. We analyzed gender, age,
type of BP, incidence, and local etiological factors and assessed the relationship between these factors and the
clinical findings at the first oral examination.
Results: MRONJ was found in nine male patients (6.9%). The mean patient age was 62.2 years. The median BP
administration time was 19 months. Seven patients were treated with a combination of IV zoledronate and pamidronate,
and two patients received single-agent therapy. The lesions were predominantly located in the mandible (n = 8), and the
most common predisposing dental factor was a history of prior extraction (n= 6). Half of the MRONJ were related to
diseases found on the initial dental screen. Patients with MRONJ were treated with infection control and antibiotic
therapy. When comparing between the MRONJ stage and each factor (sign, location, etiologic factor, BP type, treatment,
and outcome), there were no significant differences between stages, except for between the stage and sign (with or
without purulence).
Conclusions: For prevention of MRONJ, we recommend routine dental examinations and treatment prior to starting
BP therapy.
Keywords: Multiple myeloma, Bisphosphonate, Medication-related necrosis of the jaw
Background
Multiple myeloma (MM) is characterized by a neoplastic
proliferation of plasma cells mostly within the bone mar-
row [1]. MM comprises 0.5% of all cancers in Korea [2].
Worldwide annual incidence is 1.5 per 100,000 individuals.
Anemia, renal dysfunction, infections, and bone lesions
are the most common complications of MM. In the major-
ity of patients, slow and steady progressive bone damage,
or osteolytic lesions, may lead to fractures of the long
bones or compression fractures in the spine. Bone pain is
often a symptom of this disease, especially severe back
pain. Bisphosphonates (BPs) are used in the management
of MM as supportive therapy to inhibit the progression of
osteoclast activity, which reduces skeletal-related morbid-
ity and mortality [3].
BPs are non-metabolized pyrophosphate analogues that
are capable of localizing in bone and inhibiting osteoclast
function [4]. These drugs act at the site of active bone re-
modeling by binding to hydroxyapatite, inhibiting osteo-
clast development and migratory activity. Inhibiting
osteoclast function leads to cell death, which decreases
bone resorption without affecting bone mineralization [5].
These non-metabolized analogues are maintained at high
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concentrations in bone resorption lacunae for an extended
period, allowing long-term inhibition of osteoclastic func-
tion. In addition, BPs can inhibit bone resorption and
decrease bone turnover at the tissue level, as assessed by
biochemical markers [4].
In addition to oral BPs used for osteoporosis and osteo-
genesis imperfecta, intravenous BPs are effective in the
treatment and management of several conditions. Intraven-
ous (IV) BPs treat cancer-related conditions, including
hypercalcemia of malignancy, lytic lesions in MM, and the
effects of bone metastasis in the context of solid tumors,
such as breast cancer, prostate cancer, and lung cancer. In
metastatic disease to the bone, BPs prevent skeletal
complications, reduce bone pain, and improve the quality
of life. Additionally, there is some evidence that BPs also
have anti-tumor activity. Bisphosphonate therapy is recom-
mended for all patients with multiple myeloma requiring
chemotherapy, whether bone lesions are evident or not [6].
Adverse effects associated with the use of BP include
pyrexia, gastrointestinal symptoms, hypocalcemia, and
renal dysfunction [3, 7]. In 2003, Marx [8] described
bisphosphonate-related osteonecrosis of the jaw (BRONJ)
as a new complication associated with nitrogen-
containing BP use. The American Association of Oral
and Maxillofacial Surgeons (AAOMS) published a
position paper providing guidance regarding the pre-
vention, diagnosis, and treatment of BRONJ according
to the different stages. BRONJ is diagnosed when BP
administration is followed by bone exposure that does
not heal within 8 weeks of identification and when pa-
tients have no history of local radiation therapy [9, 10].
Recently, the term medication-related osteonecrosis of
the jaw (MRONJ) was introduced in the updated
AAOMS position paper discussing bisphosphonate-
related osteonecrosis of the jaw. This updated paper
accommodates the growing number of osteonecrosis
cases involving the maxilla and mandible associated with
other anti-resorptive (denosumab) and anti-angiogenic
therapies.
Presently, few reports addressing the epidemiology of
MRONJ in patients with MM have been published.
Furthermore, few studies with stage and treatment strat-
egies that are recommended by the AAOMS have been
published yet. The aim of this study was to analyze the
incidence of MRONJ in multiple myeloma patients and to
analyze the systemic and local risk factors, including stage
and clinical outcome, with standard treatments recom-
mended by the AAOMS position paper. This report focuses
on both medical and dental databases at a single-center.
Methods
This retrospective study included MM patients with a
history of intravenous bisphosphonate therapy at the
Department of Hematology, St. Mary’s Hospital of the
College of Medicine, The Catholic University of Korea,
who had been referred to the Department of Dentistry
for oral examination or dental care. MRONJ was defined
when all of the following characteristics were present:
(1) current or previous treatment with BPs, (2) exposed
bone in the maxillofacial region persisting for more than
8 weeks, and (3) no history of radiation to the jaw. We
recorded patients’ clinical signs and symptoms, including
the location of exposed and necrotic bone, evidence of
infection, pain, and the extent of osteolysis. Based on
these findings, we applied the staging and treatment
strategies described by the AAOMS position paper on
MRONJ to each patient (Table 1) [10]. We analyzed gen-
der, age, type of BP, incidence, and local etiological fac-
tors, including their relationship to the clinical findings
at the first oral examination. The institutional review
board of St. Mary’s Hospital approved this study.
For statistical analysis, SAS software package (Version
9.3, SAS Institute) was used. Categorical variables such
as sign, location, etiologic factors, BP type, treatment,
and outcome were analyzed by Fisher’s exact tests, and
continuous variables such as duration were analyzed by
Wilcoxon tests. A p value <0.05 was considered statisti-
cally significant.
Results
A total of 130 MM patients visited the Department of
Dentistry. There were 57 females and 74 males. The
mean patient age was 57 years (range 36–76 years). At
the initial dental examination, we found 50 cases with
calculus deposition, 29 cases with dental caries, 25 cases
with periodontal diseases, 24 cases with third molar dis-
ease, 14 cases with periapical lesions, and 30 cases with
other diseases, including hypersensitivity, cervical abra-
sion, and attrition. Only two cases of MRONJ associated
with tooth extraction were present. In addition, we saw
15 MM cases without dental disease (Fig. 1). However,
seven of these patients later developed MRONJ. Overall,
jaw necrosis occurred after bisphosphonate therapy in
nine cases (6.9%). These patients were all male, and the
mean patient age was 62.2 years. The median length of
BP exposure was 19 months (range 8–69 months). All
patients received intravenous BP therapy. Seven of the
patients were treated with a combination of zoledronate
and pamidronate, one patient received zoledronate
alone, and one received pamidronate alone. Four of the
patients were also given an oral bisphosphonate (pano-
nin) (Table 2). The observed lesions were predominantly
located in the mandible. Only one case had a maxillary
lesion. At the initial visit, only two of the patients with
MRONJ presented with exposed bone at the extraction
socket. In the remaining patients, we found periodontal
diseases (n = 5), calculus deposition (n = 2), mucosal
irritation (n = 1), third molar problems (n = 1), and
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periapical lesions (n = 2). Half of the MRONJ cases
occurred at sites that were related to the diseases seen at
the initial visit. The most common predisposing dental
factor was dental extraction (n = 6), followed by pros-
thesis irritation (n = 2), and periodontal therapy (n = 1)
(Fig. 2). However, one patient developed MRONJ spon-
taneously (Fig. 3).
According to the AAOMS staging system, five cases
were stage II, two cases were stage I, and one case was
stage III. One patient progressed from stage 0 to stage II
after the biopsy. This patient showed a fistula of
unknown origin under the bridge pontic. The Bone scan
revealed intense hot uptake in the mandible in this
patient, and CT and biopsy exhibited chronic osteomye-
litis likely secondary to actinomycosis. However, a few
days after the bone biopsy, the bone became exposed
despite repair with a primary suture (Fig. 1).
The main treatment methods for patients with MRONJ
focus on infection control and antibiotic therapy as recom-
mended by the AAOMS. One patient with stage I MRONJ
died after the treatment due to underlying disease, and
two patients were lost to follow-up. All six remaining
patients presented with non-healing exposed bone during
the follow-up. Five of the six patients were stage I, and the
remaining patient was stage II. Notably, this stage II
patient did not improve with treatment (Table 2).
When comparing between stage and each factor (sign,
location, etiologic factor, BP type, treatment, and out-
come), there were no significant differences between
groups, except for between the stage and sign (with or
without pus) (Table 3).
Discussion
The exact mechanism of action underlying the pathogen-
esis of MRONJ is uncertain. MRONJ may be associated
with medication-related apoptosis of osteoclasts or to the
anti-angiogenic and suppressive effects that BPs have on
endothelial cells [11]. The strong association of intravenous
nitrogen-containing BPs with MRONJ compared to oral
BPs suggests that intravenous BPs are more bioavailable,
allowing increased incorporation into the bone matrix.
Only 1% of oral BPs are circulated in the serum due to
delayed gastrointestinal tract absorption.
The prevalence of MRONJ in patients treated with
intravenous BPs ranges from 0.8 to 12% [10]. According
to a cohort study, the estimated incidence of MRONJ in
MM patients is 8.42%, and the highest incidence is in
Table 1 Staging and treatment strategies described by the American Association of Oral and Maxillofacial Surgeons position paper
on MRONJ of the jaw
MRONJ staging Description Treatment strategies
At risk category No apparent necrotic bone in patients who have
been treated with either oral or IV bisphosphonates
No treatment indicated
Patient education
Stage 0 No clinical evidence of necrotic bone but non-specific
clinical findings and symptoms
Systemic management, including use of
pain medication and antibiotics
Stage 1 Exposed and necrotic bone in patients who are asymptomatic
and have no evidence of infection
Antibacterial mouth rinse.
Clinical follow-up on a quarterly basis.
Patient education and review of indications
for continued bisphosphonate therapy.
Stage 2 Exposed and necrotic bone associated with infection as
evidenced by pain and erythema in the region of the
exposed bone with or without purulent drainage
Symptomatic treatment with oral antibiotics.
Oral antibacterial mouth rinse.
Pain control.
Superficial debridement to relieve soft tissue irritation.
Stage 3 Exposed and necrotic bone in patients with pain, infection,
and one or more of the following: exposed and necrotic bone
extending beyond the region of alveolar bone (i.e., inferior
border and ramus in the mandible, maxillary sinus and zygoma
in the maxilla) resulting in pathologic fracture, extra-oral fistula,
oral antral/oral nasal communication, or osteolysis extending to
the inferior border of the mandible of sinus floor
Antibacterial mouth rinse.
Antibiotic therapy and pain control.
Surgical debridement/resection for long-term
palliation of infection and pain.
Fig. 1 Distribution of the dental problems in multiple myeloma
patients at their initial visit
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Table 2 Clinical characteristics of MM patients with MRONJ





II (Bone exposure, pus
discharge, pain)





Bone exposure (stage I)
2
II (Bone exposure, pus
discharge, pain)





Bone exposure (stage I)
3
II (Bone exposure, pus
discharge, pain)
Mandible molar Tooth extraction Zoledronate (15)
I&D, antibiotics,
dressing
Bone exposure (stage I)
4 II (Bone exposure, pain) Mandible molar Tooth extraction
Zoledronate,
Pamidronate (69)
Antibiotics, Dressing Bone exposure (stage I)
5
II (Bone exposure, pus
discharge, pain)






6 I (Bone exposure) Mandible molar Spontaneous
Zoledronate,
pamidronate (25)
Antibiotics, dressing Bone exposure (stage I)
7
II (Bone exposure, pus
discharge, pain)




Bone exposure with pain
(stage II)
8
III (Pain, Osteolytic lesion
on Mn. Basal bone)
Mandible molar Tooth extraction Pamidronate (8) Antibiotics, dressing No f/u





Bone exposure state (died
due to systemic disease)
Fig. 2 Distribution of cases according to the preceding events
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patients who received a combination of pamidronate and
zoledronate (range 5 to 51%). Zoledronate is associated
with MRONJ in 3 to 11% of MM cases, while the
pamidronate-related frequency of MRONJ ranges from 0
to 18% [3]. The overall incidence of MRONJ in our study
was 6.9% (9/130 MM patients). Of these nine patients,
77.7% (n = 7) received a combination of pamidronate and
zoledronate.
Studies evaluating the duration of bisphosphonate ther-
apy as a risk factor for MRONJ development in MM
patients have yielded inconsistent results [6, 9]. In our
patients, the median length of BP exposure was 19 months,
which is similar to the results of Berenson et al. (18 months
of zoledronate) [12]. However, our results are not consist-
ent with those of Corso et al. [13] (47 months of pamidro-
nate and zoledronate combination therapy), Zervas et al.
[14] (24 months of pamidronate), and Dimopoulos et al.
(53.4 months of pamidronate and zoledronate combin-
ation therapy) [15].
It is thought that the jaw is more predisposed to
MRONJ compared to other bones. This may be due to
healing of open bone wounds, vulnerability to bacterial
infections, and that BPs are preferentially deposited in bone
with higher turnover rates, such as the jaw [16, 17]. Wen et
al. [18] supported the theory that BPs preferentially
deposit into bones with higher rates of remodeling,
such as the jaw, relative to non-oral sites. Using athymic
rats, they demonstrated a significantly higher release of
hydroxyapatite-bound bisphosphonate in oral bones com-
pared to axial and appendicular sites. After injection of
fluorescent pamidronate into the mice, more signal was de-
tected and was retained for longer time periods in the man-
dible than in the femur [19], which demonstrates that the
mandible has a high affinity for BPs. Notably, MRONJ is
twice as common in the mandible as in the maxilla [10].
Marx et al. [20] reported that 68.1% of the MRONJ cases
occur in the mandible and 27.7% occur in the maxilla.
Similar results were found in a study by Bardos et al. [5],
where 15 of 22 MM patients with MRONJ showed man-
dibular lesions, five showed both mandibular and maxillary
lesions, and two were in the maxilla only. In our study, only
one patient presented with MRONJ in the maxilla. One
possible explanation for osteonecrosis secondary to BP use,
especially in the mandible, may be BP’s anti-angiogenic
effects, or the anatomic and physiologic features of the
mandible might increase the risk of MRONJ [21, 22]. Un-
fortunately, the exact mechanism underlying the higher in-
cidence of MRONJ in the mandible remains unknown.
In MRONJ, dental extraction is the biggest local risk
factor [6]. The surgical damage to the jaw that occurs
after extraction, especially the damage to the alveolar
bone with open bone wounds, seems to be the most po-
tent trigger for MRONJ. In extractions, jaw bone re-
modeling is depressed, leading to the spontaneous
breakdown of the wound after the tooth is removed.
Notably, the site of the pre-existing bone might not be
of prime importance. Woven bone is not altered by
BPs, but remodeling of woven bone into lamellar bone
might be impaired, leading to MRONJ [23]. Patients re-
ceiving intravenous BPs and undergoing dentoalveolar
Fig. 3 Clinical features and CT of MRONJ patient. a Mucosal fistula on the pontic area. b Intraoperative findings during bone biopsy. c Exposed
alveolar bone. d CT findings
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treatment are at least seven times more likely to de-
velop MRONJ than those who are not [5, 10]. Tooth
extraction is associated with 77% of MRONJ cases in
the patients with intravenously administrated BPs [6].
In our study, the most common risk factor for MRONJ
was dental extraction (n = 6), followed by prosthesis ir-
ritation (n = 2), periodontal therapy (n = 1), and un-
known causes (n = 1). Half of the MRONJ locations
coincided with the site of the dental problem seen at
the first visit.
This retrospective study has some limitations. Firstly,
we did not evaluate the patients’ oral health prior to ini-
tiating bisphosphonate therapy. However, we found that
periodontal disease, including calculus deposition, was
the most frequent dental disease in the MM patients at
the initial dental examination such as in them with
MRONJ. Aside from the two patients who initially
presented with MRONJ, the majority of MM patients
had periodontal problems, such as calculus deposition
(n = 50), periodontal lesions (n = 25), and dental caries
(n = 29). These results are similar to those of MM pa-
tients with MRONJ. In MM with MRONJ, the most
common dental disease was periodontal disease (n = 5),
followed by calculus deposition (n = 2), periapical lesions
(n = 2), mucosal irritation (n = 1), and third molar prob-
lems (n = 1). Thus, clinical examinations, including
panoramic radiography, may help detect dental problems
and improve oral health before and during bisphospho-
nate therapy.
Based on our data, prevention of MRONJ is optimal
because its management is quite challenging. While
some case reports have demonstrated surgical treatment
with good outcomes, generally, aggressive surgery has
been counterproductive, often exacerbating the bone
exposure [24]. Hence, most publicized studies suggest
that initial treatment (stage I, II) should be conservative,
focusing on systematic antibiotic therapy, irrigation to
optimize oral hygiene, and careful removal of sequesters
[10, 17, 25]. However, only 23–53% of all patients
achieve resolution of mucosal discontinuities [26, 27].
Bamias et al. [7] demonstrated that antibiotic therapy re-
sulted in temporary improvement, but only one patient
showed sustained improvement of their osteonecrosis
after multiple courses of antibiotics. The remaining 11
MM patients with MRONJ had persistent disability,
mainly experiencing recurrence with purulent discharge
and pain after discontinuing their antibiotics. These
results coincide well with ours. In this present study,
after conservative treatment as recommended by the
AAOMS, the majority of stage II patients has been
improved and was reclassified as stage I, but all patients
remained with unhealed exposed bone at the follow-up
appointment.
Conclusions
Osteonecrosis of the jaw has been recognized as a ser-
ious complication of intravenous BP treatment, espe-
cially in patients with MM. We found that the majority
of MM patients with MRONJ received a combination
of pamidronate and zoledronate. The mandible, par-
ticularly at molar extraction sites, was the most fre-
quent area affected. In some patients, the location of
MRONJ and the type of dental problem coincided with
the oral condition seen at the initial visit. Management
regimens that lead to complete resolution of MRONJ
remain elusive. While conservative therapy improved
some conditions, all patients were left with some
remaining exposed bone. Therefore, the prevention of
MRONJ is crucial. Routine dental examinations and
treatment of dental diseases should be performed prior
to initiating bisphosphonate therapy.
Table 3 Comparing patients with MRONJ between MM stages
according to each factor (sign, location, etiologic factor, BP type,
treatment, and outcome) of MM
Stage
1 2 3 P value
Number of patients 2 6 1
Location (%) 1
Mandible 2 (100) 5 (83.33) 1 (100)
Maxilla 0 (0) 1 (16.67) 0 (0)
Infection (%) 0.0476*
Yes 0 (0) 5 (83.33) 0 (0)
No 2 (100) 1 (16.67) 1 (100)
Etiology (%) 0.7222
Extraction 1 (50) 3 (50) 1 (100)
Prosthesis problem 0 (0) 2 (33.33) 0 (0)
Periodontal problem 0 (0) 1 (16.67) 0 (0)
Spontaneous 1 (50) 0 (0) 0 (0)
Bisphosphonate type (%) 0.25
Combinationa 2 (100) 5 (83.33) 0 (0)
Only zoledronate 0 (0) 1 (16.67) 0 (0)
Only pamidronate 0 (0) 0 (0) 1 (100)
Treatmentb (%) 0.6429
Conservative 2 (100) 3 (50) 1 (100)
Invasive 0 (0) 3 (50) 0 (0)
Outcome (%) 1
1 1 (100) 4 (80) 0 (0)
2 0 (0) 1 (20) 0 (0)
Duration in months 21 (17–25) 19 (11–69) 9 (9–9) 0.2992
Categorical variables such as sign, location, etiologic factor, BP type, treatment,
and outcome were analyzed by Fisher’s exact test. Continuous variables such
as duration were analyzed by Wilcoxon test
*Statistically significant (p value <0.05)
aCombination of zoledronate and pamidronate
bConservative: antibiotic therapy and dressing invasive: biopsy or saucerization
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